Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to Revolutionizing the Nicotine Industry with its Alternative Nicotine Delivery
Lexaria’s recent animal study on its patented DehydraTECH(TM) technology on nicotine absorption yielded ground-breaking results This study builds on an earlier 2018 study that demonstrated effective delivery of nicotine to the central nervous system in a rodent study The study’s success will serve as the foundation for a human trial that will compare the DehydraTECH-nicotine pouch performance to leading brands Zacks Small Cap Research recently did a deep dive on Lexaria Bioscience (NASDAQ: LEXX) and its contribution to alternative nicotine delivery. Its evaluation acknowledged that the global tobacco market is currently valued at $818 billion, mainly sustained by over 1.1…